The new blood-based screening tool represents an alternative to a standard clot-based FVIII test which cannot accurately determine inhibitor levels in patients receiving Hemlibra®.
The AAVs being being investigated are designed to target the human liver, drawing on the organs potential to produce clotting factor.
Much of the data for this analysis was drawn from the HAVEN clinical trial program, which was designed to assess the efficacy and safety of emicizumab in hemophilia A patients with and without FVIII inhibitors.
Bayer has responded to NHF's and HFA's queries regarding the recall.
Meet the team who are dedicating their 26-mile run to NHF.
Bayer has responded to NHF and HFA's questions about the recall of Kogenate® FS.
The company is developing gene therapies for both hemophilia A and B, and for several other chronic conditions.
NHF and HFA submitted a letter to Bayer requesting more information about the recall.
Concizumab is being investigated for the prevention of bleeding episodes in hemophilia A patients, and in hemophilia A/B patients with inhibitors.
Both AAV vectors and genome editing novel technologies are being brought to bear in this unique and experimental gene therapy.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car